Skip to search formSkip to main contentSkip to account menu

abiraterone acetate

Known as: Abiraterone Acetate [Chemical/Ingredient] 
An orally active acetate salt of the steroidal compound abiraterone with antiandrogen activity. Abiraterone inhibits the enzymatic activity of… 
National Institutes of Health

Related topics

Related topics

16 relations

Broader (2)

Antineoplastic AgentsCytochrome P-450 Enzyme Inhibitors

Narrower (2)

CB 7630Zytiga
Cytochrome P450 17A1 Inhibitors [MoA]In BloodNCIt Antineoplastic Agent TerminologySteroid 17-alpha-Hydroxylase

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Cell-Free DNA Modification Dynamics in Abiraterone Acetate-Treated Prostate Cancer Patients
Purpose: Primary resistance to abiraterone acetate (AA), a key medication for the treatment of metastatic castration-resistant… 
2018
2018
Quantitation of the anticancer drug abiraterone and its metabolite &Dgr;(4)‐abiraterone in human plasma using high‐resolution mass spectrometry
2014
2014
Differential response to abiraterone acetate and di-n-butyl phthalate in an androgen-sensitive human fetal testis xenograft bioassay.
In utero exposure to antiandrogenic xenobiotics such as di-n-butyl phthalate (DBP) has been linked to congenital defects of the… 
Review
2014
Review
2014
No clear evidence of a clinical benefit of a sequential therapy regimen with abiraterone acetate and enzalutamide
Prostate cancer is the second leading cause of cancer-related deaths in men in most western countries. New agents for metastatic… 
2014
2014
Public biotech 2013—the numbers
2013 was truly a year to remember for the public biotech sector, with the largest wave of IPOs since the 2000–2001 bubble. 
2013
2013
Emerging Molecularly Targeted Therapies in Castration Refractory Prostate Cancer
Androgen deprivation therapy (ADT) with medical or surgical castration is the mainstay of therapy in men with metastatic prostate… 
Review
2012
Review
2012
Putting the brakes on continued androgen receptor signaling in castration-resistant prostate cancer
Review
2011
Review
2011
Abiraterone Acetate, A Novel Adrenal Inhibitor in Metastatic Castration-Resistant Prostate Cancer
The androgen receptor remains the key player in patients with castration-resistant prostate cancer (CRPC). Available agents… 
Review
2010
Review
2010
Abiraterone acetate for castration resistant prostate cancer
Importance of the field: Androgen deprivation therapy has been the standard of care in advanced prostate cancer for > 50 years… 
2008
2008
Abiraterone acetate and prednisone in patients (Pts) with progressive metastatic castration resistant prostate cancer (CRPC) after failure of docetaxel-based chemotherapy
5019 Background: A proportion of CRPC overexpress androgen synthetic enzymes and are dependent on androgens for growth… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)